Audentes’ $86 Million Shelf-Takedown Offering

Cooley advised the underwriters on Audentes Therapeutics’ $86.3 million shelf-takedown offering of 5,955,151 shares of common stock, which includes 755,151 shares purchased pursuant to the underwriters’ option to purchase additional shares.

BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering. Wedbush PacGrow acted as a co-manager.

Audentes Therapeutics, which trades on The NASDAQ Global Market as “BOLD,” is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.

Cooley has advised with a team led by Drew Williamson (Picture), Charlie Kim and David Peinsipp.

Involved fees earner: Drew Williamson – Cooley LLP; Charlie Kim – Cooley LLP; David Peinsipp – Cooley LLP; Kristin VanderPas – Cooley LLP; Denny Won – Cooley LLP; Sunny Chang – Cooley LLP; Natasha Leskovsek – Cooley LLP; Phil Mitchell – Cooley LLP; Rebecca Ross – Cooley LLP; Kevin King – Cooley LLP; Nan Wu – Cooley LLP; Aaron Nudelman – Cooley LLP; Danish Hamid – Cooley LLP; Laura McDaniels – Cooley LLP; Susan Cooper Philpot – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Bank of America Merrill Lynch; Piper Jaffray & Co; Cowen and Company; Wedbush PacGrow;

Print Friendly, PDF & Email

Author: Ambrogio Visconti